US2006144735A1PendingUtilityA1

Method and packaging for pressurized containers

49
Assignee: AVENTIS PHARMA LTDPriority: Jun 26, 2002Filed: Feb 27, 2006Published: Jul 6, 2006
Est. expiryJun 26, 2022(expired)· nominal 20-yr term from priority
B65D 81/268A61M 2209/06A61M 15/009B65D 75/26A61M 2202/062
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for maintaining the enclosed volume of a sealed package at about ambient pressure, wherein the package contains a pressurized container comprising a drug, and an HFA (hydrofluoroalkane) propellant selected from the group consisting of HFA 134a and HFA p227, or a mixture thereof; wherein the method comprises the steps of (1) positioning an effective amount of a HFA adsorbent material, and said pressurized container, within a sealable package; (2) sealing the package so that the pressurized container and adsorbent are in an enclosed volume within the package at a pressure equal to about ambient pressure; and (3) adsorbing any leakage of the HFA propellant into the HFA adsorbent material so as to maintain the enclosed volume at about ambient pressure.

Claims

exact text as granted — not AI-modified
1 . A method for maintaining the enclosed volume of a sealed package at about ambient pressure, wherein the package contains pressurized MDI (metered dose inhaler) container comprising a drug, and an HFA (hydrofluoroalkane) propellant selected from the group consisting of HFA 134a and HFA p227, or a mixture thereof; wherein the method comprises the steps of: 
 (i) positioning an effective amount of a HFA adsorbent material, and said pressurized container, within a sealable package;    (ii) sealing the package so that the pressurized container and adsorbent are in an enclosed volume within the package at a pressure equal to about ambient pressure; and    (iii) adsorbing any leakage of the HFA propellant into the HFA adsorbent material so as to maintain the enclosed volume at about ambient pressure.    
   
   
       2 . The method according to  claim 1 , wherein the drug is selected from the group consisting of bronchodilators, antihistamines, lung surfactants, antiviral agents, corticosteroids, ant-inflammatory agents, anti-cholinergics, and antibiotic.  
   
   
       3 . The method according to  claim 1 , wherein the pressurized MDI (metered dose inhaler) container further comprises one or more excipients selected from the group consisting of surfactants, preservatives, flavorings, antioxidants, anti-aggregating agents and co-solvents.  
   
   
       4 . The method according to  claim 1 , wherein the HFA propellant is HFA 134a.  
   
   
       5 . The method according to  claim 1 , wherein the HFA propellant is HFA p227.  
   
   
       6 . The method according to  claim 1 , wherein the HFA adsorbent material is capable of adsorbing the HFA propellant up to about 25% of the weight of the adsorbent.  
   
   
       7 . The method according to  claim 1 , wherein the HFA gas adsorbent material is capable of adsorbing the HFA propellant up to about 20% of the weight of the adsorbent.  
   
   
       8 . The method according to  claim 1 , wherein the HFA adsorbent material comprises material selected from the group consisting of molecular sieves, activated clays, activated alumina, silica, zeolites, bauxites, and mixtures thereof.  
   
   
       9 . The method according to  claim 1 , wherein the package is permeable to HFA p227.  
   
   
       10 . The method according to  claim 9 , wherein the package has a permeability to HFA p227 that is less than or equal to about 0.25 cc of HFA p227 per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       11 . The method according to  claim 9 , wherein the package has a permeability to HFA p227 that is less than or equal to about 0.15 cc of HFA p227 per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       12 . The method according to  claim 9 , wherein the package has a permeability to HFA p227 that is less than or equal to about 0.10 cc of HFA p227 per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       13 . The method according to  claim 9 , wherein the package has a permeability to HFA p227 that is less than or equal to about 0.05 cc of HFA p227 per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       14 . The method according to  claim 1 , wherein the package is permeable to HFA 134a.  
   
   
       15 . The method according to  claim 14 , wherein the package has a permeability to HFA 134a that is less than or equal to about 4.1 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       16 . The method according to  claim 14 , wherein the package has a permeability to HFA 134a that is less than or equal to about 3.5 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       17 . The method according to  claim 14 , wherein the package has a permeability to HFA 134a that is less than or equal to about 2.5 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       18 . The method according to  claim 14 , wherein the package has a permeability to HFA 134a that is less than or equal to about 1.5 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       19 . The method according to  claim 14 , wherein the package has a permeability to HFA 134a that is less than or equal to about 1.0 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       20 . The method according to  claim 14 , wherein the package has a permeability to HFA 134a that is less than or equal to about 0.5 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       21 . The method according to  claim 1 , wherein the package is made of metal, glass, or plastic, and is selected from the group consisting of bottles, bags, drum boxes, and irregularly shaped containers.  
   
   
       22 . The method according to  claim 1 , wherein the package is made of plastic.  
   
   
       23 . The method according to  claim 22 , wherein the plastic is a flexible laminate having a barrier layer providing said package with permeability to HFA 134a and/or HFA p227.  
   
   
       24 . The method according to  claim 1 , wherein the sealed package is hermetically sealed by heat-sealing, gluing, welding, brazing, mechanical closures or clamps, or compression.  
   
   
       25 . Use of an HFA adsorbent to maintain the pressure of an enclosed volume within a sealed package at about ambient pressure, wherein the sealed package comprises: 
 (i) a pressurized MDI (metered dose inhaler) container comprising a drug, a HFA (hydrofluoroalkane) propellant selected from the group consisting of HFA 134a and HFA p227, or a mixture thereof;    (ii) an effective amount of an HFA adsorbent material; 
 wherein the pressurized MDI container and HFA adsorbent material are within the enclosed volume of the sealed package.  
   
   
   
       26 . The use according to  claim 25 , wherein the drug is selected from the group consisting of bronchodilators, antihistamines, lung surfactants, antiviral agents corticosteroids, ant-inflammatory agents, anti-cholinergics, and antibiotics.  
   
   
       27 . The use according to  claim 25 , wherein the pressurized MDI (metered dose inhaler) container further comprises one or more excipients selected from the group consisting of surfactants, preservatives, flavorings, antioxidants, anti-aggregating agents and co-solvents.  
   
   
       28 . The use according to  claim 25 , wherein the HFA propellant is HFA 134a.  
   
   
       29 . The use according to  claim 25 , wherein the HFA propellant is HFA p227.  
   
   
       30 . The use according to  claim 25 , wherein the HFA adsorbent material is capable of adsorbing the HFA propellant up to about 25% of the weight of the adsorbent.  
   
   
       31 . The use according to  claim 25 , wherein the HFA gas adsorbent material is capable of adsorbing the HFA propellant up to about 20% of the weight of the adsorbent.  
   
   
       32 . The use according to  claim 25 , wherein the HFA adsorbent material comprises material selected from the group consisting of molecular sieves, activated clays, activated alumina, silica, zeolites, bauxites, and mixtures thereof.  
   
   
       33 . The use according to  claim 32 , wherein the HFA adsorbent material is 10 Å (Angstrom) molecular sieves.  
   
   
       34 . The use according to  claim 33 , wherein the molecular sieves, in an amount of about 4 grams, absorbs about 230 ml of HFA p227.  
   
   
       35 . The use according to  claim 33 , wherein the molecular sieves, in an amount of about 4 grams, absorbs about 230 ml of HFA 134a.  
   
   
       36 . The use according to  claim 25 , wherein the package is impermeable to HFA 134a.  
   
   
       37 . The use according to  claim 25 , wherein the package is impermeable to HFA p227.  
   
   
       38 . The use according to  claim 25 , wherein the package is permeable to HFA p227.  
   
   
       39 . The use according to  claim 38 , wherein the package has a permeability to HFA p227 that is less than or equal to about 0.25 cc of HFA p227 per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       40 . The use according to  claim 38 , wherein the package has a permeability to HFA p227 that is less than or equal to about 0.15 cc of HFA p227 per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       41 . The use according to  claim 38 , wherein the package has a permeability to HFA p227 that is less than or equal to about 0.10 cc of HFA p227 per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       42 . The use according to  claim 38 , wherein the package has a permeability to HFA p227 that is less than or equal to about 0.05 cc of HFA p227 per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       43 . The use according to  claim 25 , wherein the package is permeable to HFA 134a.  
   
   
       44 . The use according to  claim 43 , wherein the package has a permeability to HFA 134a that is less than or equal to about 4.1 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       45 . The use according to  claim 43 , wherein the package has a permeability to HFA 134a that is less than or equal to about 3.5 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       46 . The use according to  claim 43 , wherein the package has a permeability to HFA 134a that is less than or equal to about 2.5 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       47 . The use according to  claim 43 , wherein the package has a permeability to HFA 134a that is less than or equal to about 1.5 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       48 . The use according to  claim 43 , wherein the package has a permeability to HFA 134a that is less than or equal to about 1.0 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       49 . The use according to  claim 43 , wherein the package has a permeability to HFA 134a that is less than or equal to about 0.5 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       50 . The use according to  claim 25 , wherein the package is made of metal, glass, or plastic, and is selected from the group consisting of bottles, bags, drum boxes, and irregularly shaped containers.  
   
   
       51 . The use according to  claim 50 , wherein the package is made of plastic.  
   
   
       52 . The use according to  claim 51 , wherein the plastic is a flexible laminate having a barrier layer providing said package with impermeability to HFA 134a and/or HFA p227.  
   
   
       53 . The use according to  claim 51 , wherein the plastic is a flexible laminate having a barrier layer providing said package with permeability to HFA 134a and/or HFA p227.  
   
   
       54 . The use according to  claim 52 , wherein said flexible laminate has three layers: polyester/aluminum/polyethylene, wherein the aluminum layer is between the polyester and polyethylene layers.  
   
   
       55 . The use according to  claim 52 , wherein said barrier layer is made of aluminum foil.  
   
   
       56 . The use according to  claim 25  wherein the sealed package is hermetically sealed by heat-sealing, gluing, welding, brazing, mechanical closures or clamps, or compression.  
   
   
       57 . A pharmaceutical product comprising: 
 (i) a pressurized MDI (metered dose inhaler) container comprising a drug, and an HFA (hydrofluoroalkane) propellant selected from the group consisting of HFA 134a and HFA p227, or a mixture thereof;    (ii) an effective amount of an HFA adsorbent material; and    (iii) a sealed package having an enclosed volume within which the pressurized container and the HFA adsorbent material are situated, wherein the pressure within the enclosed volume of the package is equal to about ambient pressure; 
 wherein the HFA adsorbent material is capable of adsorbing the HFA propellant so as to maintain a constant pressure within said enclosed volume, when any leakage of the HFA propellant occurs from the pressurized container; and  
 wherein the package has a permeability to HFA p227 that is less than or equal to about 0.25 cc of HFA p227 per square meter of package per day at about 1 bar pressure and about room temperature, or a permeability to HFA 134a that is less than or equal to about 4.1 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
   
       58 . A pharmaceutical product according to  claim 57 , wherein the package has a permeability to HFA p227 that is less than or equal to about 0.15 cc of HFA p227 per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       59 . A pharmaceutical product according to  claim 57 , wherein the package has a permeability to HFA p227 that is less than or equal to about 0.10 cc of HFA p227 per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       60 . A pharmaceutical product according to  claim 57 , wherein the package has a permeability to HFA p227 that is less than or equal to about 0.05 cc of HFA p227 per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       61 . A pharmaceutical product according to  claim 57 , wherein the package has a permeability to HFA 134a that is less than or equal to about 3.5 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       62 . A pharmaceutical product according to  claim 57 , wherein the package has a permeability to HFA 134a that is less than or equal to about 2.5 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       63 . A pharmaceutical product according to  claim 57 , wherein the package has a permeability to HFA 134a that is less than or equal to about 1.5 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       64 . A pharmaceutical product according to  claim 57 , wherein the package has a permeability to HFA 134a that is less than or equal to about 1.0 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       65 . A pharmaceutical product according to  claim 57 , wherein the package has a permeability to HFA 134a that is less than or equal to about 0.5 cc of HFA 134a per square meter of package per day at about 1 bar pressure and about room temperature.  
   
   
       66 . A pharmaceutical product according to  claim 57 , wherein the drug is selected from the group consisting of bronchodilators, antihistamines, lung surfactants, antiviral agents, corticosteroids, ant-inflammatory agents, anti-cholinergics, and antibiotics.  
   
   
       67 . A pharmaceutical product according to  claim 57 , wherein the pressurized MDI (metered dose inhaler) container further comprises one or more excipients selected from the group consisting of surfactants, preservatives, flavorings, antioxidants, anti-aggregating agents and co-solvents.  
   
   
       68 . A pharmaceutical product according to  claim 57 , wherein the HFA propellant is HFA 134a.  
   
   
       69 . A pharmaceutical product according to  claim 57 , wherein the HFA propellant is HFA p227.  
   
   
       70 . A pharmaceutical product according to  claim 57 , wherein the HFA adsorbent material is capable of adsorbing the HFA propellant up to about 25% of the weight of the adsorbent.  
   
   
       71 . A pharmaceutical product according to  claim 57 , wherein the HFA gas adsorbent material is capable of adsorbing the HFA propellant up to about 20% of the weight of the adsorbent.  
   
   
       72 . A pharmaceutical product according to  claim 57 , wherein the HFA adsorbent material comprises material selected from the group consisting of molecular sieves, activated clays, activated alumina, silica, zeolites, bauxites, and mixtures thereof.  
   
   
       73 . A pharmaceutical product according to  claim 57 , wherein the package is made of metal, glass, or plastic, and is selected from the group consisting of bottles, bags, drum boxes, and irregularly shaped containers.  
   
   
       74 . A pharmaceutical product according to  claim 73 , wherein the package is made of plastic.  
   
   
       75 . A pharmaceutical product according to  claim 74 , wherein the plastic is a flexible laminate having a barrier layer providing said package with permeability to HFA 134a and/or HFA p227.  
   
   
       76 . A pharmaceutical product according to  claim 75 , wherein said flexible laminate has three layers: polyester/aluminum/polyethylene, wherein the aluminum layer is between the polyester and polyethylene layers.  
   
   
       77 . A pharmaceutical product according to  claim 75 , wherein said barrier layer is made of aluminum foil.  
   
   
       78 . A pharmaceutical product according to  claim 57 , wherein the sealed package is hermetically sealed by heat-sealing, gluing, welding, brazing, mechanical closures or clamps, or compression.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.